BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/19/2020 3:26:25 AM | Browse: 289 | Download: 405
 |
Received |
|
2020-09-11 16:01 |
|
Peer-Review Started |
|
2020-09-11 16:02 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-09-24 16:31 |
|
Revised |
|
2020-10-08 04:19 |
|
Second Decision |
|
2020-10-20 12:32 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-10-20 21:20 |
|
Articles in Press |
|
2020-10-20 21:20 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-11-08 14:46 |
|
Publish the Manuscript Online |
|
2020-11-18 14:20 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Frontier |
| Article Title |
Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Frank-Un Hong, Miguel Castro and Klaus Linse |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Frank-Un Hong, PhD, Research Scientist, Department of Research and Development, Bio-Synthesis, 612 E. Main St., Lewisville, TX 75057, United States. fhong@coh.org |
| Key Words |
Retinoblastoma protein; P53 protein; Cancer; Checkpoint; Taxol; Tumor-specific lytic path |
| Core Tip |
Side effect remains a major impediment to achieving a cure. An important advance has been made to establish the principle of cytotoxic cancer therapy at the mechanistic level. It concerns the discovery of the tumor-specific lytic path “hyperploid progression mediated death” targeting retinoblastoma (or p53) mutants defective in G1 DNA damage checkpoint. By triggering the lytic path, tumor specificity can be achieved at the genetic level for cytotoxic drugs. |
| Publish Date |
2020-11-18 14:20 |
| Citation |
Hong F, Castro M, Linse K. Tumor-specific lytic path “hyperploid progression mediated death”: Resolving side effects through targeting retinoblastoma or p53 mutant. World J Clin Oncol 2020; 11(11): 854-867 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i11/854.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i11.854 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
